JP6511430B2 - がんの治療のための化合物および組成物 - Google Patents

がんの治療のための化合物および組成物 Download PDF

Info

Publication number
JP6511430B2
JP6511430B2 JP2016501185A JP2016501185A JP6511430B2 JP 6511430 B2 JP6511430 B2 JP 6511430B2 JP 2016501185 A JP2016501185 A JP 2016501185A JP 2016501185 A JP2016501185 A JP 2016501185A JP 6511430 B2 JP6511430 B2 JP 6511430B2
Authority
JP
Japan
Prior art keywords
optionally substituted
mmol
compound
nmr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512520A (ja
JP2016512520A5 (enExample
Inventor
ルイス エイ ティモシー
ルイス エイ ティモシー
ムニョス ベニート
ムニョス ベニート
ドゥ ヴァール ルシアン
ドゥ ヴァール ルシアン
グロイリッヒ ハイジ
グロイリッヒ ハイジ
マイヤーソン マシュー
マイヤーソン マシュー
ニコール ゲチジャン ララ
ニコール ゲチジャン ララ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2016512520A publication Critical patent/JP2016512520A/ja
Publication of JP2016512520A5 publication Critical patent/JP2016512520A5/ja
Application granted granted Critical
Publication of JP6511430B2 publication Critical patent/JP6511430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016501185A 2013-03-11 2014-03-11 がんの治療のための化合物および組成物 Active JP6511430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361776520P 2013-03-11 2013-03-11
US61/776,520 2013-03-11
PCT/US2014/023263 WO2014164704A2 (en) 2013-03-11 2014-03-11 Compounds and compositions for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016512520A JP2016512520A (ja) 2016-04-28
JP2016512520A5 JP2016512520A5 (enExample) 2017-04-13
JP6511430B2 true JP6511430B2 (ja) 2019-05-15

Family

ID=50729763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501185A Active JP6511430B2 (ja) 2013-03-11 2014-03-11 がんの治療のための化合物および組成物

Country Status (4)

Country Link
US (2) US9890127B2 (enExample)
EP (1) EP2970145B1 (enExample)
JP (1) JP6511430B2 (enExample)
WO (1) WO2014164704A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615222A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 免疫疾病用藥臨床新應用
CN104478809B (zh) * 2014-11-14 2016-08-17 成都新恒创药业有限公司 一种左西孟旦杂质及其制备和检测方法
US11324746B2 (en) 2014-12-22 2022-05-10 Arovella Therapeutics Limited Use of anagrelide for treating cancer
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
CN114699528A (zh) * 2015-08-13 2022-07-05 布罗德研究所股份有限公司 用于表达pde3a或slfn12的癌症的组合物和方法
JP7148403B2 (ja) * 2016-02-05 2022-10-05 バイエル・ファルマ・アクティエンゲゼルシャフト 癌患者の層別化および癌治療のための化合物、組成物および方法
EP3414231B1 (en) * 2016-02-08 2020-08-19 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
PH12018501873B1 (en) 2016-03-04 2022-06-10 Otsuka Pharmacetical Co Ltd 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative
EP3429996A4 (en) * 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES AGAINST CEREBLON TO IMPROVE THE FUNCTION OF EFFECTOR T CELLS
CN105968054B (zh) * 2016-05-12 2018-09-14 海门慧聚药业有限公司 匹莫苯丹关键中间体的制备
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
EP3576742B1 (en) * 2017-02-03 2025-07-02 The Broad Institute, Inc. 6-[3,5-dihalogeno-4-(morpholin-4-yl)phenyl]-5-methyl-4,5-dihydropyridazin-3(2h)-one, modulators of pde3a or 3b for use in the treatment of cancer
US11897867B2 (en) * 2017-08-04 2024-02-13 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
ES2914355T3 (es) 2017-08-07 2022-06-09 Alkermes Inc Inhibidores bicíclicos de la histona desacetilasa
JP7104588B2 (ja) * 2017-09-01 2022-07-21 大塚製薬株式会社 ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
CN108997349B (zh) * 2018-06-20 2021-03-16 合肥华方医药科技有限公司 一种依匹斯汀有关物质的制备方法
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
WO2020157188A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Dihydrooxadiazinones for the treatment of hyperproliferative diseases
WO2020157201A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Oxadiazinone compounds for the treatment of hyperproliferative diseases
WO2020157199A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
JP7582953B2 (ja) 2019-02-01 2024-11-13 バイエル アクチェンゲゼルシャフト 過剰増殖性疾患を治療するための１，２，４－トリアジン－３（２ｈ）－オン化合物
CN113582974B (zh) * 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624730A (en) * 1950-08-16 1953-01-06 Sterling Drug Inc 6-haloaryl-3-pyridazones
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US3824271A (en) 1972-07-20 1974-07-16 American Cyanamid Co 3-alkyl-3-(benzoyl)propionitriles
SE375007B (enExample) 1972-11-30 1975-04-07 Pharmacia Ab
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4092311A (en) 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
FI72718C (fi) * 1981-03-04 1987-07-10 Ciba Geigy Ag Foerfarande foer framstaellning av terapeutiskt verkande, substituerade 6-(4-morfolino-fenyl)-4,5-dihydro- 3(2h)-pyridazinoner och deras syraadditionssalter.
US4717730A (en) * 1982-12-03 1988-01-05 Warner-Lambert Company 4,5-dihydro-6-(substituted)phenyl-5-methyl-3-(2H)-pyridazinones and pharmaceutical compositions containing the compounds as active components
JPS6061570A (ja) 1983-09-16 1985-04-09 Sankyo Co Ltd ピリダジノン誘導体及び農業用殺菌剤
JPS6153270A (ja) * 1984-08-17 1986-03-17 チバ・ガイギー・アクチエンゲゼルシヤフト 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤
GB8426804D0 (en) * 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
DE3531658A1 (de) 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5053338A (en) * 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH05140116A (ja) 1991-11-21 1993-06-08 Nippon Soda Co Ltd 光学活性な化合物
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
EP0791584A4 (en) 1994-11-11 1997-11-19 Nippon Soda Co OPTICALLY ACTIVE CONNECTIONS
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6525053B1 (en) * 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
NZ574873A (en) * 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors
JP2010013354A (ja) * 2006-09-07 2010-01-21 Kyorin Pharmaceut Co Ltd ２−アルキル−６−（ピラゾロピリジン−４−イル）ピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
CN101538245B (zh) * 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途

Also Published As

Publication number Publication date
US20160016913A1 (en) 2016-01-21
US20180244629A1 (en) 2018-08-30
EP2970145B1 (en) 2020-05-06
WO2014164704A3 (en) 2014-12-31
EP2970145A2 (en) 2016-01-20
JP2016512520A (ja) 2016-04-28
US9890127B2 (en) 2018-02-13
WO2014164704A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
JP6511430B2 (ja) がんの治療のための化合物および組成物
KR102218333B1 (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
AU2014298051B2 (en) Novel quinazolinones as bromodomain inhibitors
JP3649395B2 (ja) 縮合ヘテロアリール誘導体
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
KR100737090B1 (ko) 축합 이미다졸륨 유도체
BR112014015720B1 (pt) Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
JPWO2020017587A1 (ja) ピリダジノン誘導体
TW201927792A (zh) 作為溴結構域蛋白質抑制劑的化合物和組合物
CN103038229A (zh) 杂芳基化合物及其使用方法
BR112013002375B1 (pt) Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto
BR122023004130B1 (pt) Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1
BR112019014688A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
TW201910329A (zh) 取代五元并六元雜環類化合物、其製備方法、藥物組合及其用途
CA2946475A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
WO2022199676A1 (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
WO2014159938A1 (en) Substituted aminothiazoles for the treatment of tuberculosis
BR112017004035B1 (pt) Inibidores macrocíclicos de rip2 quinase e composições farmacêuticas
TW202043209A (zh) Mek抑制劑及其在醫藥上的應用
CN105367472B (zh) 吲哚啉类衍生物及其在药物上的应用
CN117295743A (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
JP7175878B2 (ja) 新規ベンズイミダゾロン化合物およびその医薬用途
TW206230B (enExample)
JP2023536442A (ja) オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用
CN106045967B (zh) 取代杂环化合物及其在药物上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190408

R150 Certificate of patent or registration of utility model

Ref document number: 6511430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250